Table 3.
Antagonist and synergistic agents of BaP.
| Models | Treatment | Effects | Reference | |
|---|---|---|---|---|
| Antagonist agent | Resolvin D1 | HUVECs | ↓ BaP-induced CYP1A1, PTGS2, COX2, cPGES, ↑ GSTM1 level; and ↑ cPLA2, ↓ CYP1A1 activity | (97) |
| Flavonoids | HUVECs | ↓ BaP-induced ICAM1 expression in HUVEC | (98) | |
| Hesperidin | Human EAhy-926 cells | ↓ BaP-induced AhR activation, ↑ ABCA1, ↓ IL-1β and TNFα, ↓ LDL accumulation | (99) | |
| Ostreococcus tauri and Phaeodactylum tricornutum Extracts | Human micro-vascular endothelial cell | ↓ cell apoptosis and extracellular vesicles, ↓ CYP1A1, IL-8 and IL1-β | (100) | |
| Budesonide-poly(lactide-co-glycolide) | A/J mice | ↓ BaP-induced oxidative stress, and vascular leakage, ↓ VEGF and c-myc expression | (101) | |
| Soluble epoxide hydrolase inhibitor | Sprague-Dawley rats | reversed the BaP-induced CYP1A1, CYP1B1, CYP4F4, and CYP4F5 ↑ | (102) | |
| Ginkgo biloba extract | Stomach Neoplasms mice | ↓ ameliorating cardiotoxic effects of doxorubicin, ↓ serum NO, ↓ liver cytosolic glutathione S-transferase, G6PDH activity | (103) | |
| Synergistic agent | 1,25(OH)2D3 | THP-1 and U937 cells | ↑ BaP-DNA adduct formation | (104) |
| Carbon black particles | Human EAhy-926 cells | ↑ cell proliferation, migration and invasion, and metabolism, ↓ PPARγ activity | (105) | |
| SiNPs | HUVECs | ↑ ROS, DNA damage, cell cycle arrest, ↑ bax, caspase-3, and caspase-9, ↓ Cdc25C, cyclin B1, bcl-2 | (106) | |
| Zebrafish embryos | ↑ inflammation and coagulation, ↑ pAP-1/c-Jun, CD142 | (107) | ||
| Zebrafish embryos | signaling pathway alteration such as MAPK, PI3K-Akt, JAK/STAT | (108) |
“↑” means up-regulation and “↓” means down-regulation.